Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: can it predict the optimal number of instillations?

J Urol. 1999 Jan;161(1):67-71. doi: 10.1097/00005392-199901000-00024.

Abstract

Purpose: In patients with superficial bladder cancer treated with a first 6-week instillation course of bacillus Calmette-Guerin (BCG) the induction pattern of urinary interleukin (IL)-2 has been described, and the levels of urinary IL-2 were associated with the clinical response to BCG treatment. We evaluated urinary IL-2 kinetics in patients with recurrent superficial bladder tumor receiving a second or third 6-week BCG instillation course. To our knowledge there have been no studies of prolonged BCG treatment and urinary cytokine responses.

Materials and methods: Urinary IL-2 was determined in 12 patients with superficial transitional cell carcinoma of the bladder receiving a complete (6-week) second or third BCG instillation course and in 3 patients receiving 3 BCG instillations during a maintenance schedule at month 3. Urinary IL-2 was determined with an enzyme-linked immunosorbent assay using an oligoclonal system.

Results: Of 12 patients 10 had a urinary IL-2 positive response during the subsequent BCG course and at week 1 urinary IL-2 was already increased. Comparing the urinary IL-2 kinetics observed during a second or third with a first course, urinary IL-2 tended to be higher during the first and lower during the last weeks. If the interval between subsequent courses was short (12 months or less) significantly higher urinary IL-2 levels at weeks 1 and 2, and a lower level at week 6 were observed.

Conclusions: During a repeat BCG instillation course urinary IL-2 reached a maximum at an earlier week, especially if the interval between the subsequent courses was short. Since an association between urinary IL-2 levels and response to BCG treatment during an induction course has been observed, these immunological data argue in favor of a limited number of instillations during prolonged BCG therapy which could reduce side effects as well as costs.

Publication types

  • Clinical Trial

MeSH terms

  • Adjuvants, Immunologic / administration & dosage*
  • Administration, Intravesical
  • BCG Vaccine / administration & dosage*
  • Carcinoma, Transitional Cell / therapy*
  • Carcinoma, Transitional Cell / urine*
  • Humans
  • Interleukin-2 / urine*
  • Monitoring, Physiologic
  • Neoplasm Recurrence, Local / therapy*
  • Neoplasm Recurrence, Local / urine*
  • Predictive Value of Tests
  • Time Factors
  • Urinary Bladder Neoplasms / therapy*
  • Urinary Bladder Neoplasms / urine*

Substances

  • Adjuvants, Immunologic
  • BCG Vaccine
  • Interleukin-2